Compare Gilead Sciences, Inc. (GILD) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Carparts.Com Inc — how do they compare? Gilead Sciences, Inc. trades at $135.59 (market cap $163.51B), while Carparts.Com Inc trades at $5.55 (market cap $46.57M). The key difference: Gilead Sciences, Inc. is far larger — about 3511.1× Carparts.Com Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.
| GILD | PRTS | |
|---|---|---|
Market Cap | $163.51B | $46.57M |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $11.40 |
52-Week Low | $108.22 | $3.88 |
Enterprise Value | $178.05B | $61.54M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
PRTS trades at $5.66, down 3.99% today, with a bearish technical signal but recent earnings beats. The company reported a net loss of $50.44M in 2025, though revenue was $547.53M. A recent reverse stock split and new credit facility aim to stabilize operations. Analyst consensus is 60% buy with no sell ratings, indicating Wall Street optimism despite financial challenges.
Outlook hinges on cost control and revenue stabilization; risks include persistent losses and competitive pressures. The stock presents a speculative opportunity if operational improvements continue, but investors face significant downside if turnaround efforts falter amid weak cash flow and negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
